Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Functional longevity of maternally derived antibodies against group B Streptococcus and respiratory syncytial virus in HIV-exposed uninfected and HIV-unexposed uninfected infants.

Award Number: R21HD114232
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/11/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2025

Group Awards By:

View Award Description

Functional longevity of maternally derived antibodies against group B Streptococcus and respiratory syncytial virus in HIV-exposed uninfected and HIV-unexposed uninfected infants. - Group B streptococcus (GBS) and respiratory syncytial virus (RSV) are the primary causes of neonatal and infant deaths with HIV-exposed uninfected infants bearing the highest brunt of disease. Although there are no licensed vaccines against GBS and RSV, maternal vaccines are currently being developed and some promising candidates are completing phase III clinical trials. Maternal vaccines are considered the optimal strategy to prevent disease in both pregnant women and their respective infants. However, due to the low incident rate per study setting for GBS, determining vaccine efficacy via phase III clinical trials could be logistically infeasible. Therefore, to expedite vaccine licensure and implementation, an alternative pathway would be to conduct immuno-bridging studies to establish antibody concentrations correlated with disease protection as targets to measure vaccine immunogenicity in these vulnerable populations. HIV infection impairs B cell immunity leading to the generation of defective antibodies. This could therefore ultimately impact the efficacy of maternal vaccines against GBS and/or RSV in conferring protection to infants including those that are HIV-exposed but uninfected. Since 95-99% of infant mortality cases related to GBS and RSV occur in low-middle income countries (LMIC) where HIV infection is prevalent, it is crucially important to consider how this would impact antibody thresholds and functional longevity required to confer protection to the young. Moreover, clinical epidemiological studies report higher incidence of mortality cases amongst HIV- exposed uninfected infants (iHEU) attributable to GBS and RSV diseases compared to HIV-unexposed uninfected infants (iHUU). iHEU account for 20-30% of newborns in LMIC with ~1 million iHEU born each year. To ensure that this vulnerable infant population is protected by the maternal vaccines being developed, immunological parameters that could influence passive immunity in mother-infant pairs need to be established for consideration when evaluating GBS and RSV immunogenicity in clinical trials. Although there is consensus evidence that trans-placental antibody transfer is poor in iHEU compared to iHUU, there are a limited studies reporting the kinetic profile and functionality of these transferred antibodies, and with even fewer studies describing how HIV infection impacts breast milk antibodies against GBS and RSV. Using an existing longitudinal INFANT cohort consisting of plasma and breastmilk samples, we propose to quantify mother-infant antibody concentrations and functional kinetics to determine whether they are compromised by HIV-infection (mother) or HIV-exposure (infant); information that is currently missing in existing literature. Our study therefore proposes to use multiplex immunoassays to measure and compare antibody concentrations, avidity, and function against GBS and RSV between iHEU and iHUU to establish parameters to be achieved for an effective maternal vaccine in high HIV endemic regions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $114,410 )
2025	2025	UNIVERSITY OF CAPE TOWN	LOVERS WALK	CAPE TOWN				ZAF	Child Health and Human Development Extramural Research	000	2	12/19/2024	NON-COMPETING CONTINUATION	$114,410
														Subtotal = $114,410

Issue Date FY: 2024 ( Subtotal = $150,257 )
2024	2024	UNIVERSITY OF CAPE TOWN	LOVERS WALK	CAPE TOWN				ZAF	Child Health and Human Development Extramural Research	000	1	1/11/2024	NEW	$150,257
														Subtotal = $150,257

Grand Total All Awards = $264,667

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Functional longevity of maternally derived antibodies against group B Streptococcus and respiratory syncytial virus in HIV-exposed uninfected and HIV-unexposed uninfected infants.

Award Number: R21HD114232

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/11/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer